These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 17620694)

  • 1. Safety and reactogenicity of a low dose diphtheria tetanus acellular pertussis vaccine (Boostrix) in pre-school Indian children.
    Bose A; Dubey AP; Gandhi D; Pandit A; Raghu MB; Raghupathy P; Rao MI; Verghese VP; Datta SK; Bock HL
    Indian Pediatr; 2007 Jun; 44(6):421-4. PubMed ID: 17620694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine as a single-dose booster in Singaporean adults.
    Chan SH; Tan PT; Han HH; Bock HL
    Singapore Med J; 2006 Apr; 47(4):286-90. PubMed ID: 16572239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
    Zepp F; Knuf M; Habermehl P; Mannhardt-Laakmann W; Howe B; Friedland LR
    J Pediatr; 2006 Nov; 149(5):603-610. PubMed ID: 17095328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
    Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
    Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
    Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
    Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine?
    Halperin SA; Sweet L; Baxendale D; Neatby A; Rykers P; Smith B; Zelman M; Maus D; Lavigne P; Decker MD
    Pediatr Infect Dis J; 2006 Mar; 25(3):195-200. PubMed ID: 16511379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
    Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
    Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of combined diphtheria tetanus whole cell pertussis hepatitis B/ Haemophilus influenzae type b vaccine in Indian infants.
    Bavdekar SB; Maiya PP; Subba Rao SD; Datta SK; Bock HL
    Indian Pediatr; 2007 Jul; 44(7):505-10. PubMed ID: 17684303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine in healthy Taiwanese children and adolescents.
    Huang LM; Chang LY; Tang H; Bock HL; Lu CY; Huang FY; Lin TY; Lee CY
    J Adolesc Health; 2005 Dec; 37(6):517. PubMed ID: 16310132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunogenicity and reactogenicity of a reduced antigen content diphtheria, tetanus and acellular pertussis vaccine dTpa) in 10 to 11 years old children and in adults].
    Abarca K; Valdivieso F; Potin M; Ibáñez I; Vial P
    Rev Med Chil; 2002 May; 130(5):502-10. PubMed ID: 12143270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of the reactogenicity of a three-component acellular pertussis vaccine and whole-cell pertussis vaccine administered to healthy Singaporean infants.
    Shek LP; Khor ES; Tan GH; Low KT; Ong D; Roy J; Han HH; Bock HL; Lee BW
    Southeast Asian J Trop Med Public Health; 2003 Dec; 34(4):863-8. PubMed ID: 15115101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective assessment of the effect of needle length and injection site on the risk of local reactions to the fifth diphtheria-tetanus-acellular pertussis vaccination.
    Jackson LA; Starkovich P; Dunstan M; Yu O; Nelson J; Dunn J; Rees T; Zavitkovsky A; Maus D; Froeschle JE; Decker M
    Pediatrics; 2008 Mar; 121(3):e646-52. PubMed ID: 18310184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The safety and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis (dTpa) booster vaccine in healthy Vietnamese children.
    Anh DD; Jayadeva G; Kuriyakose S; Han HH
    Vaccine; 2016 Aug; 34(37):4360-3. PubMed ID: 27435387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR, at age 4-6 years.
    Marshall H; Nolan T; Roberton D; Richmond P; Lambert S; Jacquet JM; Schuerman L
    Vaccine; 2006 Aug; 24(35-36):6120-8. PubMed ID: 16822597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules.
    Pichichero ME; Casey JR; Francis AB; Marsocci SM; Murphy M; Hoeger W; Cleary C
    Clin Pediatr (Phila); 2006 Sep; 45(7):613-20. PubMed ID: 16928838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.
    Zepp F; Habermehl P; Knuf M; Mannhardt-Laakman W; Howe B; Friedland LR
    Vaccine; 2007 Jul; 25(29):5248-52. PubMed ID: 17583395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine.
    McIntyre PB; Turnbull FM; Egan AM; Burgess MA; Wolter JM; Schuerman LM
    Vaccine; 2004 Dec; 23(3):380-5. PubMed ID: 15530684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactogenicity of acellular pertussis vaccine in 4-year-olds in The Netherlands.
    Keijzer-Veen MG; Holty-van der Wekken L; Juttmann RE; de Groot R; Rümke HC
    Vaccine; 2004 Sep; 22(25-26):3256-7. PubMed ID: 15308347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine.
    Thisyakorn U; Pancharoen C; Chuenkitmongkol S; Ortiz E
    Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):282-94. PubMed ID: 19323013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
    Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
    Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.